NCT00487123

CompletedPhase 4

Efficacy of the New Closure Device in Improving Patient Comp...

Novartis Source

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

CVAH631BSG02

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

1

Timeline

Study Start

Not reported

Date not reported

Primary Completion

September 2007

Actual (reported)

Study Completion

September 2007

Actual (reported)

Brief Summary

This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Reported enrollment (type unavailable): Not reported
Study completion date: September 2007
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
June 13, 2007
Actual (reported)
First Posted
June 15, 2007
Actual (reported)
Primary Completion
September 2007
Actual (reported)
Study Completion
September 2007
Actual (reported)

Last Updated: June 17, 2008
Status Verified: June 2008
Last Update Submitted: June 13, 2008

Conditions

Hypertension

Keywords

Hypertension, compliance, Valsartan, hydrochlorothiazide (HCTZ)

Outcome Measures

Primary Outcomes (1)

Compliance rate at month 3, 6 and post study month 1 will be assessed by pill count

Secondary Outcomes (1)

Patient Adherence to study/follow up visits -Clinical Outcome Measurement: Mean sitting systolic BP and mean sitting diastolic BP -Patient's and Physician's Satisfaction Survey

Interventions

Valsartan+/- HydrochlorothiazideDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Valsartan+/- Hydrochlorothiazide
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age21 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients with hypertension that have newly started using Valsartan+/-HCTZ

You may not qualify if:

Sponsors & Collaborators

Novartis
Industrylead

Study Sites (1)

Novartis Investigative Site

Singapore, Singapore

MeSH Terms

Conditions

HypertensionPatient Compliance

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesPatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

non IND
Sponsor GmbH
STUDY CHAIR

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

June 13, 2007

First Posted

June 15, 2007

Primary Completion

September 2007

Actual (reported)

Study Completion

September 2007

Actual (reported)

NCT00760266

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population

Phase 4Completed

NCT00400777

Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension

Phase 4Completed

NCT00426478

Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients

Phase 4Completed

NCT00171054

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

Phase 4Completed

NCT00171561

Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.

Phase 4Completed

NCT00698646

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Phase 4Completed

Pregnancy or Hypersensitivity to Valsartan+/-HCTZ

Contact the study team to confirm eligibility.

Last Updated

June 17, 2008

Record last verified: 2008-06

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00487123
Data provider: ClinicalTrials.gov
Source updated: 2008-06-17
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:24:26 UTC

Locations

SG(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations